Date: 2012-10-16
Type of information: Services contract
Compound: services including generation of induced pluripotent stem (iPS) cell lines of clinical grade and differentiation of iPS cells toward specific tissue cell type of clinical grade.
Company: Cellectis (France) NIH (USA)
Therapeutic area:
Type agreement: services
Action mechanism:
Disease:
Details: Cellectis bioresearch, the specialist in genome customization and commercial subsidiary of Cellectis has been awarded a contract to provide services to the National Institutes of Health (NIH) and certain other government agencies. Under the terms of the contract, the scope of work includes generation of induced pluripotent stem (iPS) cell lines of clinical grade and differentiation of iPS cells toward specific tissue cell type of clinical grade.
Financial terms: This multiple award, indefinite delivery/indefinite quantity (IDIQ) contract, has a maximum order limit of $9,509,000 over a period of five years.
Latest news:
